Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) EBITDA Margin (2020 - 2022)

SELLAS Life Sciences (SLS) has disclosed EBITDA Margin for 3 consecutive years, with 1673.5% as the latest value for Q1 2022.

  • Quarterly EBITDA Margin fell 163411.0% to 1673.5% in Q1 2022 from the year-ago period, while the trailing twelve-month figure was 4195.0% through Dec 2022, down 386218.0% year-over-year, with the annual reading at 4195.0% for FY2022, 386218.0% down from the prior year.
  • EBITDA Margin for Q1 2022 was 1673.5% at SELLAS Life Sciences, down from 234.37% in the prior quarter.
  • The five-year high for EBITDA Margin was 39.39% in Q1 2021, with the low at 1673.5% in Q1 2022.
  • Average EBITDA Margin over 3 years is 541.54%, with a median of 226.63% recorded in 2021.
  • Peak annual rise in EBITDA Margin hit -163411bps in 2022, while the deepest fall reached -163411bps in 2022.
  • Over 3 years, EBITDA Margin stood at 218.89% in 2020, then fell by -7bps to 234.37% in 2021, then tumbled by -614bps to 1673.5% in 2022.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 1673.5%, 234.37%, and 39.39% for Q1 2022, Q2 2021, and Q1 2021 respectively.